HIFU - Novelty or innovation (Dr. Jim Hu)
Dr. Jim C. Hu speaks on the promising technology and controversy surrounding HIFU treatment for prostate cancer.
Dr. Jim C. Hu in the Washington Post - Almost all men with early prostate cancer survive 10 years, regardless of treatment
Dr. Hu speaks to the Washington Post regarding a new study that looks at 15 year mortality rates for prostate cancer patients. We look closer at the role of PSA testing in aging men and how to appropriately manage diagnosis early stage prostate cancer.
Jim C. Hu, M.D. - Expert Urges Revisiting PSA Screening After Pivotal Trial Update
The PSA screening conversation continues with the latest update from OncLive, featuring Dr. Jim C. Hu.
Dr. Jim Hu on Reevaluating PSA and the PLCO Trial OncLiveTV
Should We Abandon PSA Testing Or Make it More Targeted?
This article from Cancer Therapy Advisor features Dr. Jim Hu and resident Dr. Jonathan Shoag, continuing coverage of the PSA screening conversation.
Reevaluating PSA Testing Rates in the PLCO Trial
Dr. Jim C. Hu and Dr. Jonathan Shoag detail the controversy surrounding PSA testing. Read more at the New England Journal of Medicine here.
Jim C. Hu
Dr. Jim Hu is a urologic oncologist with his undergraduate degree in Economics, his Master’s in Public Health in HealtPolicy and Management from Johns Hopkins University, and his Medical Degree from Baylor College of Medicine. He completed his Urology Residency at the David Geffen School of Medicine at UCLA and his Robotic Surgery/Urologic Oncology Fellowship in 2004 at City of Hope National Medical Center.
